Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jul;37(7):723-733.
doi: 10.1007/s10654-022-00868-3. Epub 2022 Apr 30.

Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study

Affiliations
Meta-Analysis

Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study

Shuai Yuan et al. Eur J Epidemiol. 2022 Jul.

Abstract

The risk factors for nonalcoholic fatty liver disease (NAFLD) have not been clearly identified. We conducted a Mendelian randomization (MR) study to explore this. Independent genetic variants strongly associated with 5 lifestyle and 9 metabolic factors were selected as instrumental variables from corresponding genome-wide association studies (GWASs). Summary-level data for NAFLD were obtained from a GWAS meta-analysis of 8434 cases and 770,180 non-cases (discovery dataset) and another GWAS meta-analysis of 1483 cases and 17,781 non-cases (replication dataset). Univariable and multivariable MR analyses were performed. There were associations with NAFLD for lifetime smoking index (odds ratio (OR) 1.59, 95% confidence interval (CI) 1.31-1.93 per SD-increase), body mass index (BMI, OR 1.33, 95% CI 1.23-1.43 per SD-increase), waist circumference (OR 1.82; 95% CI 1.48-2.24 per SD-increase), type 2 diabetes (OR 1.21, 95% CI 1.15-1.27 per unit increase in log-transformed odds), systolic blood pressure (OR 1.17; 95% CI 1.07-1.26 per 10 mmHg increase), high-density lipoprotein cholesterol (OR 0.84, 95% CI 0.77-0.90 per SD-increase), and triglycerides (OR 1.23, 95% CI 1.15-1.33 per SD-increase). The associations for type 2 diabetes, systolic blood pressure, triglycerides, but not for high-density lipoprotein cholesterol remained strong after adjusting for genetically-predicted BMI. Genetic liability to type 2 diabetes mediated 51.4% (95% CI 13.4-89.3%) of the BMI-effects on NAFLD risk. There were suggestive inverse associations of genetically-predicted alcohol, coffee, and caffeine consumption, and vigorous physical activity with NAFLD risk. This study identified several lifestyle and metabolic factors that may be causally implicated in NAFLD.

Keywords: Lifestyle; Mendelian randomization; Metabolic factor; Nonalcoholic fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

DG is employed part-time by Novo Nordisk. All authors declare no support from any organization for the submitted work.

Figures

Fig. 1
Fig. 1
Study design overview
Fig. 2
Fig. 2
Associations of genetically predicted lifestyle and metabolic factors with risk of nonalcoholic fatty liver disease in discovery, replication, and combined datasets. CI confidence interval, OR odds ratio
Fig. 3
Fig. 3
Genetically predicted BMI-adjusted associations of genetically predicted waist circumference, diabetes, systolic blood pressure, and lipids with risk of nonalcoholic fatty liver disease in combined dataset. CI confidence interval, MVMR multivariable Mendelian randomization, OR odds ratio, UVMR univariable Mendelian randomization

Similar articles

Cited by

References

    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi: 10.1002/hep.28431. - DOI - PubMed
    1. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18(Suppl 1):172–253. doi: 10.1111/ajt.14559. - DOI - PubMed
    1. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904. doi: 10.1016/j.jhep.2018.05.036. - DOI - PubMed
    1. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752. doi: 10.1016/s2468-1253(20)30077-7. - DOI - PubMed
    1. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864. doi: 10.1053/j.gastro.2020.01.052. - DOI - PubMed

Publication types

MeSH terms